Weight Loss Programs for Kidney Cancer

This trial explores the most effective weight-loss strategy for individuals with kidney cancer who have small renal masses and are under observation without immediate treatment. It compares two programs: Continuous Energy Restriction, which limits daily calories, and intermittent fasting, which involves fasting for 2 days a week and eating normally for 5 days. Researchers aim to determine which plan better supports weight loss, physical health, and potentially slows cancer progression. Individuals with kidney cancer, a body mass index (BMI) of 25 or higher, and no recent significant weight loss may be suitable candidates for this trial. As an unphased trial, it offers a unique opportunity to enhance understanding of effective weight-loss strategies for kidney cancer patients.

Research has shown that both continuous energy restriction (CER) and intermittent fasting (IF) are generally safe for most people, including those with cancer. CER involves reducing calorie intake, and studies have found that cancer patients can tolerate this well. This approach is similar to the ketogenic diet, which is safe for individuals with kidney cancer. No major safety issues have been reported with these methods.

Intermittent fasting may help reduce fatigue and nausea in cancer patients and is considered safe, even when combined with treatments like chemotherapy. Some research suggests that fasting might enhance the immune system's ability to fight cancer.

Researchers are excited about exploring weight loss programs like Continuous Energy Restriction (CER) and Intermittent Fasting (IF) for kidney cancer because these approaches are non-invasive and focus on dietary changes rather than medication or surgery. Unlike standard treatments that might include surgery, targeted therapies, or immunotherapy, these methods aim to potentially slow cancer progression by leveraging metabolic changes induced by calorie restriction. The CER program involves a consistent reduction in calorie intake, while the IF program incorporates two fasting days each week, offering flexibility and potentially enhancing patient adherence. These strategies could offer a complementary option that supports traditional cancer treatments by improving overall health and potentially impacting cancer progression through metabolic pathways.

This trial will compare two weight loss programs for kidney cancer: Continuous Energy Restriction (CER) and Intermittent Fasting (IF). Research has shown that consistently eating fewer calories, known as CER, may help slow the progression of kidney cancer. Studies comparing different weight-loss methods have found that reducing daily calorie intake can help manage weight and might also slow the disease in kidney cancer patients.